|
1
|
Liu R, Zhong Y, Li X, Chen H, Jim B, Zhou
MM, Chuang PY and He JC: Role of transcription factor acetylation
in diabetic kidney disease. Diabetes. 63:2440–2453. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lai X, Zhang AH, Chen SY, He L, Su CY, Fan
MH and Wang T: Outcomes of stage 1–5 chronic kidney disease in
Mainland China. Ren Fail. 36:520–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stanton RC: Frontiers in diabetic kidney
disease: Introduction. Am J Kidney Dis. 63(2 Suppl 2): S1–S2. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roscioni SS, Heerspink HJ and de Zeeuw D:
The effect of RAAS blockade on the progression of diabetic
nephropathy. Nat Rev Nephrol. 10:77–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang RW, Zhang YL, Wang JS, Lin YY and
Shang B: Isolation and identification of flavonoids from shortscape
fleabane (Erigeron breviscapus). Zhong Cao Yao. 19:199–201.
1988.(In Chinese).
|
|
6
|
Wang M, Xie C, Cai RL, Li XH, Luo XZ and
Qi Y: Studies on antioxidant activities of breviscapine in the
cell-free system. Am J Chin Med. 36:1199–1207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang M, Zhang WB, Zhu JH, Fu GS and Zhou
BQ: Breviscapine ameliorates cardiac dysfunction and regulates the
myocardial Ca(2+)-cycling proteins in streptozotocin-induced
diabetic rats. Acta Diabetol. 47(Suppl 1): S209–S218. 2010.
View Article : Google Scholar
|
|
8
|
Jia JH, Chen KP, Chen SX, Liu KZ, Fan TL
and Chen YC: Breviscapine, a traditional Chinese medicine,
alleviates myocardial ischaemia reperfusion injury in diabetic
rats. Acta Cardiol. 63:757–762. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao W, Liu W, Wu T, Zhong D and Liu G:
Dengzhanhua preparations for acute cerebral infarction. Cochrane
Database Syst Rev. 4:CD0055682008.PubMed/NCBI
|
|
10
|
He M, Xue ZM, Li J and Zhou BQ:
Breviscapine inhibits high glucose-induced proliferation and
migration of cultured vascular smooth muscle cells of rats via
suppressing the ERK1/2 MAPK signaling pathway. Acta Pharmacol Sin.
33:606–614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang SQ and Liu JY: Effect of breviscapine
on urinary micro-albumine in patients with diabetes mellitus type
2. Zhongguo Zhong Xi Yi Jie He Za Zhi. 23:458–459. 2003.(In
Chinese). PubMed/NCBI
|
|
12
|
Wei L and Tan J: Clinical observation on
Breviscapine in treating hypertension patients complicated with
micro-albuminuria of renal impairment. Chin J Integr Med. 11:31–33.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Definition, Diagnosis and Classification
of Diabetes Mellitus and its Complications. World Health
Organisation. 1999.
|
|
14
|
American Diabetes Association. Report of
the expert committee on the diagnosis and classification of
diabetes mellitus. Diabetes Care. 7:1183–1197. 1997.
|
|
15
|
Mogensen CE, Christensen CK and Vittinghus
E: The stages in diabetic renal disease. With emphasis on the stage
of incipient diabetic nephropathy. Diabetes. 32(Suppl 2): 64–78.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Olivo SA, Macedo LG, Gadotti IC, Fuentes
J, Stanton T and Magee DJ: Scales to assess the quality of
randomized controlled trials: a systematic review. Phys Ther.
88:156–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen XH: Clinical observation of therapy
with Breviscapine for diabetic nephropathy. Zhongguo Liao Yang Yi
Xue. 16:168–169. 2007.(In Chinese).
|
|
18
|
Yu JP: Breviscapine valsartan combined
treatment of early diabetic nephropathy. Zhonghua Zhong Yi Yao Xue
Kan. 28:1337–1338. 2010.(In Chinese).
|
|
19
|
Wang XM: Impact of valsartan combined
breviscapine trace urinary albumin in diabetic nephropathy and
serum C-reactive protein. Lin Chuang He Li Yong Yao Za Zhi.
2:25–26. 2009.(In Chinese).
|
|
20
|
Huang WY: Observation of therapeutic
effects with losartan and breviscapine on early diabetic
nephropathy. Zhongguo Xiang Cun Yi Xue. 18:27–28. 2011.(In
Chinese).
|
|
21
|
Shen YF and Dai Z: Clinical observation of
therapy with candesartan and breviscapine on diabetic nephropathy.
Zhongguo Shi Yong Yi Yao. 6:148–149. 2011.(In Chinese).
|
|
22
|
Wu JY, Liang D, Ma ZH and Chen GH:
Clinical observation of therapeutic effects with irbesartan and
breviscapine on diabetic nephropathy. Guo Ji Yi Yao Wei Sheng Dao
Bao. 15:53–55. 2009.(In Chinese).
|
|
23
|
Huang WS and Sheng P: Clinical observation
of therapy with breviscapine injection on early diabetic
nephropathy. Dang Dai Yi Xue. 10:58–59. 2004.(In Chinese).
|
|
24
|
Li H: Clinical observation of treatment
effects with breviscapine injection and enalapril on 76 patients
with diabetic nephropathy. Shi Yong Lin Chuang Yi Yao Za Zhi.
10:85–86. 2006.(In Chinese).
|
|
25
|
Fang X: Evaluation of therapeutic effects
with breviscapine injection and enalapril on early diabetic
nephropathy. Dang Dai Yi Xue. 17:131–132. 2011.(In Chinese).
|
|
26
|
Qiao FB, Tian Z and He YL: Observation of
treatment with breviscapine injection and benazepril on 52 cases
with azotemia of diabetic nephropathy. Zhongguo Yao Ye. 18:55–56.
2009.(In Chinese).
|
|
27
|
Zhong L and Li K: Therapeutic effect of
Breviscapine combined with Enalapril on early diabetic nephropathy.
Hua Xi Yi Xue. 26:493–495. 2011.(In Chinese).
|
|
28
|
Liu HB, Liu CHa and Li XN: Observation of
therapeutic effects with breviscapin on 68 cases with early
diabetic nephropathy. Qingdao Yi Yao Wei Sheng. 43:41–42. 2011.(In
Chinese).
|
|
29
|
Xu YF and Yu JH: Clinical observation of
treatment with breviscapin on 36 cases with diabetic nephropathy.
Fu Jian Yi Yao Za Zhi. 30:133–134. 2008.(In Chinese).
|
|
30
|
Wu JW, Ling JH and Huang XN: Clinical
observation of treatment with breviscapin and telmisartan on early
diabetic nephropathy. Lin Chuang He Li Yongyao Za Zhi. 4:54–55.
2011.(In Chinese).
|
|
31
|
Liu SC, Wen FG and Zhao CY: Clinical
observation of treatment with breviscapin and lotensin on urinary
protein of early diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He
Za Zhi. 27:5302007.(In Chinese).
|
|
32
|
Liu SC and Zhao CY: Protective effects of
treatment with breviscapin and lotensin on early diabetic
nephropathy. Guo Ji Zhong Yi Zhong Yao Za Zhi. 29:246–247. 2007.(In
Chinese).
|
|
33
|
Jiang YF, He LQ and Shen LP: Clinical
observation on therapeutic effects of combined use of dengzhanhuasu
and losartan in treating early diabetic nephropathy. Liaoning Zhong
Yi Xue Yuan Xue Bao. 12:43–45. 2010.(In Chinese).
|
|
34
|
Zhang P: Clinical observation on
breviscapin combined with cozaar for diabetic nephropathy. Zhongguo
Yao Fang. 17:1403–1404. 2006.(In Chinese).
|
|
35
|
Qiao FB, Li CT, Li LF, Zhang CJ, He QL and
Ren LX: Clinical observation of treatment with breviscapine and
candesartan on early diabetic nephropathy. Yi Nan Bing Za Zhi.
9:606–608. 2010.(In Chinese).
|
|
36
|
Lan HP and Wu FQ: Clinical observation of
treatment with breviscapine on diabetic nephropathy. Zhengjiang Lin
Chuang Yi Xue. 10:3892008.(In Chinese).
|
|
37
|
Huang J, Wen Z and Feng Y: Clinical
observation of treatment with breviscapine on diabetic nephropathy.
Zhongguo Bao Jian Ying Yang. 9:3347–3348. 2012.(In Chinese).
|
|
38
|
Zhai SC: Analysis of treatment with
breviscapine on diabetic nephropathy. Shandong Yi Yao. 40:69–70.
2000.(In Chinese).
|
|
39
|
Wang YX: Clinical observation of therapy
with breviscapine injection on diabetic nephropathy. Zhong Wai Yi
Liao. 30:1262011.(In Chinese).
|
|
40
|
Qian F: Clinical observation of
therapeutic effects with breviscapine injection on 60 patients with
diabetic nephropathy. An Mo Yu Kang Fu Yi Xue. 2:91–92. 2011.(In
Chinese).
|
|
41
|
Li J: Observation of therapeutic effects
with breviscapine injection and valsartan on early diabetic
nephropathy. Zhongguo She Qu Yi Shi. 12:1172010.(In Chinese).
|
|
42
|
Wang W, Xing L, Wang CH and Li JC:
Influence of breviscapine injection on hemorrheology and
microcirculation of patients with diabetic nephropathy. Zhonghua
Zhong Yi Yao Xue Hui. 14:963–997. 2005.(In Chinese).
|
|
43
|
Li J, Wu LY and Wang CY: Influence of
breviscapine injection to correlated inflammatory cytokines in
patients with type 2 early diabetic nephropathy. Zhong Yao Yao Li
Yu Lin Chuang. 27:110–112. 2011.(In Chinese).
|
|
44
|
Zhao S: Observation of therapeutic effects
with breviscapin on diabetic microalbuminuria. Guiyang Zhong Yi Xue
Yuan Xue Bao. 34:37–38. 2012.(In Chinese).
|
|
45
|
Liu YC: Observation of therapeutic effects
with breviscapine on diabetic nephropathy. She Qu Zhong Yi Yao.
10:762008.(In Chinese).
|
|
46
|
Liu DK: Observation of therapeutic effects
with breviscapin on hyperviscosity in diabetic nephropathy. Hubei
Zhong Yi Za Zhi. 25:13–14. 2003.(In Chinese).
|
|
47
|
Yuan CL and Yuan LY: Clinical observation
of therapeutic effects with breviscapine on diabetic nephropathy.
Shi Yong Tang Niao Bing Za Zhi. 2:232005.(In Chinese).
|
|
48
|
Guo FH, Lv GY and Fan P: Clinical
observation of therapy with valsartan and Dengzhanhuasu for
diabetic nephropathy. Zhonghua Quan Ke Yi Xue. 6:895–896. 2008.(In
Chinese).
|
|
49
|
Huang GN, Chen JY and Zhang MY:
Hemorrheology impact of treatment with breviscapine injection on
diabetic nephropathy. Xin Zhong Yi. 38:34–35. 2006.(In
Chinese).
|
|
50
|
Cai HY: Clinical observation of treatment
with breviscapin on 30 cases with early diabetic nephropathy. Dang
Dai Yi Xue. 15:1482009.(In Chinese).
|
|
51
|
Tabák AG, Herder C, Rathmann W, Brunner EJ
and Kivimäki M: Prediabetes: a high-risk state for diabetes
development. Lancet. 379:2279–2290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Higgins GC and Coughlan MT: Mitochondrial
dysfunction and mitophagy: The beginning and end to diabetic
nephropathy? Br J Pharmacol. 171:1917–1942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Stanton RC: Clinical challenges in
diagnosis and management of diabetic kidney disease. Am J Kidney
Dis. 63(2 Suppl 2): S3–S21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Badal SS and Danesh FR: New insights into
molecular mechanisms of diabetic kidney disease. Am J Kidney Dis.
63(2 Suppl 2): S63–S83. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Mima A: Inflammation and oxidative stress
in diabetic nephropathy: New insights on its inhibition as new
therapeutic targets. J Diabetes Res. 2013:2485632013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xu XX, Zhang W, Zhang P, Qi XM, Wu YG and
Shen JJ: Superior renoprotective effects of the combination of
breviscapine with enalapril and its mechanism in diabetic rats.
Phytomedicine. 20:820–827. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Qi XM, Wu GZ, Wu YG, Lin H, Shen JJ and
Lin SY: Renoprotective effect of breviscapine through suppression
of renal macrophage recruitment in streptozotocin-induced diabetic
rats. Nephron Exp Nephrol. 104:e147–e157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhao Y, Yang QP, Xiao H, Zhao C, Liu H and
Song DP: The effect of Erigeron breviscapus on apoptosis and
expression of bax, bcl-2 in kidney of diabetic rats. Zhonghua Tang
Niao Bing Za Zhi. 17:864–867. 2009.(In Chinese).
|
|
59
|
Wagener FA, Dekker D, Berden JH,
Scharstuhl A and van der Vlag J: The role of reactive oxygen
species in apoptosis of the diabetic kidney. Apoptosis.
14:1451–1458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chadban S, Howell M, Twigg S, Thomas M,
Jerums G, Cass A, Campbell D, Nicholls K, Tong A, Mangos G, et al:
The CARI guidelines. Assessment of kidney function in type 2
diabetes. Nephrology (Carlton). 15(Suppl1): S146–S161. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang SH, Wang L, Zhou Y, Guo YJ, Yuan Y,
Li FF, Huang Y and Xia WQ: Prevalence and control of dyslipidaemia
among diabetic patients with microalbuminuria in a Chinese
hospital. Diab Vasc Dis Res. 10:169–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tomkin GH: Targets for intervention in
dyslipidemia in diabetes. Diabetes Care. 31(Suppl 2): S241–248.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Stadler K, Goldberg IJ and Susztak K: The
evolving understanding of the contribution of lipid metabolism to
diabetic kidney disease. Curr Diab Rep. 15:402015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen HC, Guh JY, Chang JM, Hsieh MC, Shin
SJ and Lai YH: Role of lipid control in diabetic nephropathy.
Kidney Int Suppl. S60–S62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Chen SC and Tseng CH: Dyslipidemia, kidney
disease and cardiovascular disease in diabetic patients. Rev Diabet
Stud. 10:88–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
